On January 7, 2016, the USPTO’s Patent Trial and Appeal Board (“Board”) issued a final written decision in an inter partes review regarding a petition filed by Ariosa Diagnostics, Inc. (“Petitioner”) over the patentability of claims 1-22 recited in U.S. Patent No. 7,955,794 (“the ‘794 Patent”). The ‘794 Patent, which issued on June 7, 2011, is owned by Illumina, Inc., and is drawn to methods of multiplexing amplification and/or genotyping reactions of target sequences to create amplicons that can be detected on an array. In the decision, the Board determined that the Petitioner had not shown by a preponderance of evidence that claims 1-22 of the ‘794 Patent are unpatentable under 35 U.S.C. § 102. The inter partes review remains pending at the Board and is captioned IPR2014-01093.
By: Jacqueline A. DiRamio